In people initiating obesity medications, liraglutide was associated with 73.6% higher first-year total health care costs than phentermine (reported interval 70.9%–76.3%).
In plain wordsIn people with obesity, liraglutide was linked to 73.6% higher first-year total health care costs than phentermine.
- Peptide
- Liraglutide
- Outcome
- IncreaseTotal health care costs in year 1
- Study
n: not reported in source
- Comparator
- Phentermine
- Outcome group
- Healthcare costs and utilization · Whole body
- Studied dose
- Dose not stated
Measurements
- Total health care cost difference
- 73.6%
- year 1 versus phentermine; reported interval 70.9%–76.3%
Source sentences
Up to 3 years after OM initiation, prescription and total health care costs were higher for all three newer OM cohorts relative to phentermine, with liraglutide having the greatest comparative increase in annual costs (e.g., total costs 73.6% [70.9%, 76.3%] higher in year 1).
2 context sentences(design, population, supporting numbers)
Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine-topiramate-ER (n = 13,888), naltrexone-bupropion-SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Multivariable difference-in-differences analyses compared the three newer drugs to phentermine for change in total annual prescription drug and health care costs, outpatient visits, and acute care use (combined emergency department visits and hospital stays).